EV-301 long-term outcomes: 24-month findings from phase 3 trial of enfortumab vedotin vs chemotherapy in previously treated advanced urothelial carcinoma Meeting Abstract
| Authors: | Rosenberg, J.; Powles, T.; Sonpavde, G.; Loriot, Y.; Duran, I.; Lee, J.; Matsubara, N.; Vulsteke, C.; Castellano, D.; Mamtani, R.; Wu, C.; Matsangou, M.; Campbell, M.; Petrylak, D.; Cathomas, R. |
| Abstract Title: | EV-301 long-term outcomes: 24-month findings from phase 3 trial of enfortumab vedotin vs chemotherapy in previously treated advanced urothelial carcinoma |
| Meeting Title: | 5th Swiss Oncology and Hematology Congress (SOHC) |
| Journal Title: | Swiss Medical Weekly |
| Volume: | 152 |
| Issue: | Suppl. 265 |
| Meeting Dates: | 2022 Nov 16-18 |
| Meeting Location: | Basel, Switzerland |
| ISSN: | 1424-7860 |
| Publisher: | E M H Swiss Medical Publishers Ltd |
| Date Published: | 2022-11-14 |
| Start Page: | 16S |
| End Page: | 17S |
| Language: | English |
| ACCESSION: | WOS:000912385900020 |
| PROVIDER: | wos |
| DOI: | 10.57187/smw.2022.40034 |
| Notes: | Meeting Abstract: 24 -- Source: Wos |
